CeriBell (NASDAQ:CBLL) CEO Xingjuan Chao Sells 39,000 Shares

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 39,000 shares of the business’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $19.90, for a total value of $776,100.00. Following the sale, the chief executive officer owned 802,317 shares of the company’s stock, valued at approximately $15,966,108.30. The trade was a 4.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Xingjuan Chao also recently made the following trade(s):

• On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.33, for a total value of $714,870.00.
• On Thursday, May 21st, Xingjuan Chao sold 6,030 shares of CeriBell stock. The stock was sold at an average price of $18.00, for a total value of $108,540.00.
• On Tuesday, May 5th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $20.10, for a total transaction of $783,900.00.

CeriBell Stock Up 1.2%

Shares of NASDAQ CBLL opened at $19.64 on Friday. The firm has a market capitalization of $745.14 million, a PE ratio of -12.05 and a beta of 0.77. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14. CeriBell, Inc. has a 1 year low of $10.85 and a 1 year high of $24.33. The firm’s 50-day moving average is $18.67 and its 200-day moving average is $19.65.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The business had revenue of $26.49 million for the quarter, compared to the consensus estimate of $26.09 million. Equities analysts expect that CeriBell, Inc. will post -1.69 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of CeriBell by 11.1% during the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after purchasing an additional 147,013 shares during the period. KCM Capital Inc grew its position in shares of CeriBell by 40.0% in the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after purchasing an additional 400,000 shares during the period. Yu Fan increased its stake in CeriBell by 10.7% during the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company’s stock worth $25,345,000 after purchasing an additional 130,964 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in CeriBell by 1,945.9% during the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after buying an additional 1,162,200 shares during the period. Finally, Novo Holdings A S raised its holdings in CeriBell by 2.3% during the 2nd quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock worth $16,857,000 after buying an additional 20,000 shares during the period.

Analyst Upgrades and Downgrades

CBLL has been the topic of a number of analyst reports. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. Canaccord Genuity Group decreased their price objective on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, CeriBell has an average rating of “Moderate Buy” and an average target price of $22.20.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.